Matthew L. Posard's most recent trade in Nautilus Biotechnology Inc was a trade of 45,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nautilus Biotechnology Inc | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2025 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,750 | 5,750 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,165 | 74,039 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 55.72 per share. | 12 Aug 2024 | 10,000 | 89,755 (0%) | 0% | 55.7 | 557,230 | Common Stock |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 56.19 per share. | 12 Aug 2024 | 10,000 | 79,755 (0%) | 0% | 56.2 | 561,930 | Common Stock |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 57.70 per share. | 12 Aug 2024 | 9,881 | 69,874 (0%) | 0% | 57.7 | 570,134 | Common Stock |
| Nautilus Biotechnology Inc | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 11 Jun 2024 | 10,000 | 109,755 (0%) | 0% | 50.0 | 500,110 | Common Stock |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 50.62 per share. | 11 Jun 2024 | 10,000 | 99,755 (0%) | 0% | 50.6 | 506,190 | Common Stock |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 8,804 | 8,804 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 6,501 | 119,755 (0%) | 0% | 0 | Common Stock | |
| Talis Biomedical Corp | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 95,000 | 95,000 | - | - | Stock option (right to buy) | |
| DermTech Inc | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 35,714 | 158,215 (1%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 11,371 | 11,371 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 8,065 | 113,254 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 55.74 per share. | 02 Dec 2022 | 10,000 | 115,189 (0%) | 0% | 55.7 | 557,370 | Common Stock |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 56.12 per share. | 02 Dec 2022 | 10,000 | 105,189 (0%) | 0% | 56.1 | 561,180 | Common Stock |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 58.80 per share. | 02 Dec 2022 | 10,000 | 125,189 (0%) | 0% | 58.8 | 588,000 | Common Stock |
| Nautilus Biotechnology Inc | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 86,467 | 86,467 | - | - | Stock Option (Right to Buy) | |
| Talis Biomedical Corp | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 95,000 | 95,000 | - | - | Stock Option (right to buy) | |
| DermTech Inc | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 26,480 | 122,501 (0%) | 0% | 0 | Common Stock | |
| Nautilus Biotechnology Inc | Matthew L. Posard | Director | Purchase of securities on an exchange or from another person at price $ 4.57 per share. | 30 Nov 2021 | 20,000 | 20,000 | - | 4.6 | 91,400 | Common Stock |
| Nautilus Biotechnology Inc | Matthew L. Posard | Director | Purchase of securities on an exchange or from another person at price $ 4.50 per share. | 30 Nov 2021 | 10,000 | 30,000 | - | 4.5 | 45,000 | Common Stock |
| Nautilus Biotechnology Inc | Matthew L. Posard | Director | Purchase of securities on an exchange or from another person at price $ 4.45 per share. | 30 Nov 2021 | 10,000 | 50,000 | - | 4.4 | 44,493 | Common Stock |
| Nautilus Biotechnology Inc | Matthew L. Posard | Director | Purchase of securities on an exchange or from another person at price $ 4.46 per share. | 30 Nov 2021 | 10,000 | 40,000 | - | 4.5 | 44,612 | Common Stock |
| Halozyme Therapeutics Inc. | Matthew L. Posard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 5,230 | 128,983 | - | 0 | Restricted Stock Units | |
| Talis Biomedical Corp | Matthew L. Posard | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 17 Feb 2021 | 62,500 | 62,500 | - | 16 | 1,000,000 | Common Stock |
| DermTech Inc | Matthew L. Posard | Director | Purchase of securities on an exchange or from another person at price $ 29.50 per share. | 11 Jan 2021 | 33,898 | 86,863 (0%) | 0% | 29.5 | 999,991 | Common Stock |